Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer
Launched by CHILDREN'S ONCOLOGY GROUP · Apr 23, 2004
Trial Information
Current as of March 23, 2025
Completed
Keywords
ClinConnect Summary
OBJECTIVES: I. Identify prospectively physician and patient factors associated with reasons why patients who are eligible for Pediatric Oncology Group therapeutic protocols are not enrolled onto such studies. II. Provide information that may be used to develop intervention strategies to decrease barriers to patient enrollment, thus increasing enrollment in therapeutic protocols.
OUTLINE: This is a case-control, multicenter study. Case patients are stratified. Stratum 1 comprises patients for whom there is an appropriate Pediatric Oncology Group (POG) frontline therapeutic protocol that has...
Gender
ALL
Eligibility criteria
- • DISEASE CHARACTERISTICS: Case or control patient clinically eligible for a Pediatric Oncology Group (POG) frontline therapeutic protocol, whether or not the protocol was submitted to or approved by the physician's Institutional Review Board Case patients must not have enrolled on the POG frontline protocol due to decision by the physician or patient/parent Control patients must have been enrolled on the POG frontline protocol Ineligible if offered treatment on an in-house therapeutic protocol (institutional review board-approved) rather than the POG protocol
- • PATIENT CHARACTERISTICS: Age: 21 and under Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified
- • PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not specified
Trial Officials
Brad H. Pollock, PhD
Study Chair
Pediatric Oncology Group Statistical Office
About Children's Oncology Group
The Children's Oncology Group (COG) is a leading national organization dedicated to improving the care and outcomes of children with cancer through collaborative research and clinical trials. Comprising a network of pediatric oncology experts, COG focuses on developing innovative treatment protocols, advancing scientific knowledge, and enhancing the quality of life for young patients. By fostering interdisciplinary collaboration and utilizing a comprehensive approach to childhood cancer, COG aims to translate research findings into effective therapies, ultimately striving for a cure for all children diagnosed with cancer.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
New York, New York, United States
Atlanta, Georgia, United States
Winston Salem, North Carolina, United States
Charleston, South Carolina, United States
Sacramento, California, United States
Gainesville, Florida, United States
Miami, Florida, United States
Tampa, Florida, United States
Honolulu, Hawaii, United States
Wichita, Kansas, United States
New Orleans, Louisiana, United States
Detroit, Michigan, United States
Flint, Michigan, United States
Hackensack, New Jersey, United States
Asheville, North Carolina, United States
Charlotte, North Carolina, United States
Greenville, North Carolina, United States
Oklahoma City, Oklahoma, United States
Providence, Rhode Island, United States
Dallas, Texas, United States
Lackland Air Force Base, Texas, United States
San Antonio, Texas, United States
Burlington, Vermont, United States
Charleston, West Virginia, United States
Milwaukee, Wisconsin, United States
Ottawa, Ontario, Canada
Montreal, Quebec, Canada
Montreal, Quebec, Canada
San Juan, , Puerto Rico
Geneva, , Switzerland
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials